Immunohistochemical and Ultrastructural Studies of 2,6-Dimethylaniline-induced Nasal Proliferative Lesions in a Rat Two-stage Nasal Carcinogenesis Model Initiated with N-bis(2-hydroxypropyl)nitrosamine
Free accessOtherFirst published online April, 2001
Immunohistochemical and Ultrastructural Studies of 2,6-Dimethylaniline-induced Nasal Proliferative Lesions in a Rat Two-stage Nasal Carcinogenesis Model Initiated with N-bis(2-hydroxypropyl)nitrosamine
Proliferative lesions induced by 2,6-dimethylaniline (DMA) in a two-stage rat nasal carcinogenesis model were immunohistochemically and ultrastructurally investigated. Male F344 rats received diet containing 3,000 ppm DMA for 52 weeks after initiation with a single subcutaneous injection of 2400 mg/kg of N-bis(2-hydroxypropyl)nitrosamine (DHPN). Histopathologically, proliferation of Bowman's glands, glandular hyperplasias, dysplastic foci, adenomas, and carcinomas were observed in treated rats. These nasal lesions mostly arose in the olfactory mucosa of the nasal cavity. Immunohistochemically, they were positive for cytokeratin and/or collagen type IV antibodies. Ultrastructurally, intracytoplasmic dense secretory granules (200—850 nm in diameter), identical to those in normal Bowman's glands, were observed in all the lesions, providing further support from an origin from these glands. Based on their cellular characterization, growth pattern and/or proliferative activity, two morphological continua were evident, one from dysplastic foci to carcinomas and the other from proliferation of Bowman's glands to glandular hyperplasias and adenomas. These results suggest that dysplastic foci arise from Bowman's glands and progress to carcinomas, while proliferation of Bowman's glands result in glandular hyperplasias and adenomas.
Boorman GA, Morgan KT, Uriah LC (1990). Nose, larynx, and trachea. In: Pathology of the Fischer Rat, Boorman GA, Eustis SL, Elwell MR, Montgomery Jr CA, MacKenzie WF (eds). Academic Press , San Diego, CA, pp 315—337.
2.
Brandt I., Brittebo EB, Feil VJ, Bakke JE (1990). Irreversible binding and toxicity of the herbicide dichlobenil (2,6-dichlorobenzonitrile) in the olfactory mucosa of mice. Toxicol Appl Pharmacol103: 491—501.
3.
Brittebo EB, Castonguay A., Furuya K., Hecht SS (1983). Metabolism of tobacco-speci fic nitrosamines by cultured rat nasal mucosa. Cancer Res43: 4343—4348.
4.
Brittebo EB, Eriksson C., Feil V., Bakke J., Brandt I. (1991). Toxicity of 2,6-dichlorothiobenzamide (chlorthiamid) and 2,6-dichlorobenzamide in the olfactory nasal mucosa of mice. Fundam Appl Toxicol17: 92—102.
5.
Brittebo EB, Löfberg B., Tjälve H. (1981). Sites of metabolism of N-nitrosodiethylamine in mice. Chem Biol Interact34: 209—221.
6.
Brittebo EB, Tjälve H. (1981). Formation of tissue-bound N'-nitrosonornicotine metabolites by the target-tissues of Sprague—Dawley and Fisher rats . Carcinogenesis11: 959—963.
7.
Brown HR (1990). Neoplastic and potentially preneoplastic changes in the upper respiratory tract of rats and mice. Environ Health Perspect85: 291— 304.
8.
Brown HR, Monticello TM, Maronpot RR, Randal HW, Hotchkiss JR, Morgan T. (1991). Proliferative and neoplastic lesions in the rodent nasal cavity. Toxicol Pathol19: 358—372.
9.
Castonguay A. , Tjälve H., Hecht SS (1983). Tissue distribution of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and its metabolites in F344 rats. Cancer Res43: 630—638.
10.
Cuschieri A., BannisterLH (1973). Somehistochemical observations on the mucosubstance s of the nasal glands of the mouse. Histochem J6: 543—558.
11.
Deamer NJ, Genter MB (1995). Olfactory toxicity of diethyldithiocarbamate (DDTC) and disulfiram and the protective effect of DDTC against the olfactory toxicity of dichlobenil. Chem Biol Interact95: 215—226.
12.
Florin I., Ritberg L., Curvall M., Enzell C. (1980). Screening of tobacco smoke constituents for mutagenicity using the Ames' test. Toxicology18: 219—232.
13.
Galloway SM, Armstrong MJ, Reuben C., Colman S., Brown B., Cannon C., Bloom AD, Nakamura F., Ahmed N., Duk S., Rimpo J., Margolin BH, Resnick MA, Anderson B., Zeiger E. (1987). Chromosome aberrations and sister chromatid exchanges in Chinese hamster ovary cells: evaluations of 108 chemicals. Environ Mol Mutagen10: 1—175.
14.
Harkema JR, Morgan KT (1996). Normal morphology of the nasal passages in laboratory rodents. In: Monographs on Pathology of Laboratory Animals, Respiratory System, 2nd ed, Jones TC, Dungworth DL, Mohr U (eds). Springer-Verlag, Berlin, pp 3—17.
15.
Haseman JK, Hailey JR (1997). An update of the National Toxicology Program database on nasal carcinogens. Mutat Res380: 3—11.
16.
Hong JY, Smith T., Lee MJ, Ma BL, Ning SM, Brady JF, Thomas PE, Yang CS ( 1991). Metabolism of carcinogenic nitrosamines by rat nasal mucosa and the effect of diallysulfide. Cancer Res51: 1509—1514.
17.
Jayyosi Z., Muc M., Knoble D., Pino M., Mirsky M., Toutain H., Cassidy K., Geigar L., Kelly M. (1998). Mechanism of species specific nasal toxicity of the phosphodiesteras e IV inhibitor RP 73401 in rat. Toxicol Sci42(S-1): 242—243 (abstract).
18.
Koujitani T. , Yasuhara K., Ikeda T., Imazawa T., Tamura T., Toyosawa K., Shimada A., Hirose M., Mitsumori K. (2000). Sequential observation of 2,6-dimethylaniline-induced nasal lesions in a rat two-stage nasal carcinogenesis model (model) after initiation with N-bis(2-hydroxypropyl)nitrosamine. J Vet Med Sci62: 751—756.
19.
Koujitani T. , Yasuhara K., Kobayashi H., Shimada A., Onodera H., Takagi H., Hirose M., Mitsumori K. (1999). Tumor-promoting activity of 2,6-dimethylaniline in a two-stage nasal carcinogenesi s model in N-bis(2-hydroxypropyl)nitrosamine-treated rats. Cancer Lett142: 161—171.
20.
Koujitani T. , Yasuhara K., Kobayashi H., Shimada A., Onodera H., Takagi H., Tamura T., Hirose M., Mitsumori K. (1999). Absence of tumor promoting activity of Xylazine in a two-stage nasal carcinogenesi s model in N-bis(2-hydroxypropyl)nitrosamine-treated rats. J Toxicol Pathol12: 203—208.
21.
Löfberg B., Brittebo EB, Tjälve H. (1982). Localization and binding of N'- nitrosonornicotine metabolites in the nasal region and in some other tissues of Sprague—Dawley rats. Cancer Res42: 2877—2883.
22.
Mitchell D. , Ibrahim S., Gusterson BA (1985). Improved immunohistochemical localization of tissue antigens using modified methacarn fixation. J Histochem Cytochem35: 491—495.
23.
Morgan KT (1994). Nasal dosimetry, lesion distribution, and thetoxicologic pathologist: A brief review. Inhal Toxicol6: 41—57.
24.
Morgan KT, Harkema JR (1996). Nasal neoplasia. In: Monographs on Pathology of Laboratory Animals, Respiratory System, 2nd ed, Jones TC, Dungworth DL, Mohr U (eds). Springer-Verlag, Berlin , pp 87—104.
25.
Nagano K., Enomoto M., Yamanouchi K., Aiso S., Katagiri T. (1988). Toxicologic pathology of upper respiratory tract . J Toxicol Pathol1: 115— 127.
26.
National Toxicology Program (NTP) (1990). Toxicology and carcinogenesis studies of 2,6-xylidine (2,6-dimethylaniline) in Charles River CD rats (feed studies). NTP Technical Report No. 278. US Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, MD.
27.
Reed CJ (1993). Drug metabolism in the nasal cavity: relevance to toxicology. Drug Metab Rev25: 173—205.
28.
Rudd CJ, Mitchell AD, Spalding J. (1983). L5178Y mouse lymphoma cell mutagenesis assay of coded chemicals incorporating analyses of the colony size distributions. Environ Mutagen5: 419.
29.
Sculler HM (1997). Nasal cavity carcinogenesi s by N-nitrosamines: A critical appraisal. Mutat Res380: 13—18.
30.
Short CR, Joseph M. (1989). Covalent binding of [14 C]-2,6-dimethylaniline to DNA of rat liver and ethmoid turbinate. J Toxicol Environ Health27: 85—94.
31.
Tjälve H., Castonguay A., Rivenson A. (1985). Microautoradiographic localization of bound metabolites in the nasal cavities of F344 rats treated with the tobacco-speci fic carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)1-butanone. J Natl Cancer Inst74: 185—189.
32.
Uraih LC, Maronpot RR (1990). Normal histology of the nasal cavity and application of special techniques. Environ Health Perspect85: 187—208.
33.
World Health Organization ( 1996). Toxicological evaluation of certain veterinary drug residues in food. WHO Food Additives Series: 38. World Health Organization, Geneva.
34.
World Health Organization ( 1998). Evaluation of certain veterinary drug residues in food . WHO Technical Report Series: 876. World Health Organization, Geneva.
35.
Zimmer D., Mazurek J., Petzold G., Bhuyan BK (1980). Bacterial mutagenicity and mammalian cell damage by several substituted anilines. Mutat Res77:317—326.
